Many life-threatening bacteria are becoming increasingly resistant to existing antibiotics. Swiss researchers co-headed by the University of Zurich have now discovered a new class of antibiotics with a unique spectrum of activity and mechanism of action. By disrupting outer membrane synthesis, the antibiotics effectively kill Gram-negative bacteria. According to the World Health Organization…
New simulation technology developed by TU Graz is designed to make the production of biopharmaceuticals more efficient, cost-effective and comprehensible for manufacturers.
A pioneering European research project designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to more patients. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint undertaking, brings together clinical scientists from international…
Acoustic Mist Ionization Mass Spectrometry (AMI-MS) has played a pivotal role in the evolution of high-throughput screening (HTS) and now steps are being taken to advance this field to other potential applications. AstraZeneca has been an important player in this area, having already run more than 10 full collection HTS campaigns against a range of enzyme target types, and the company is now…
Scientists at the German Centre for Cardiovascular Research (DZHK) have started a study to find out whether a monoclonal antibody restoring vascular integrity is safe and has positive effects on organ functions of patients with cardiogenic shock. The multicenter trial is sponsored by the University of Hamburg, financially supported by the biopharmaceutical company Adrenomed AG, and led by Dr.…
A team of seasoned European healthcare entrepreneurs announced the foundation of MCG motion capture GmbH (MCG), the world’s first precision motion analysis and digital care company. The team combines decades of expertise in the medtech, digital health and biopharmaceutical industry, including big data integration, analysis for decision support, and long-standing experience in clinical trials as…
Forty-two percent of all deaths in the United States are related to cardiovascular disease (CVD). According to the Global Cardiovascular Drugs Market Forecast, by 2030 the number of deaths from CVD will rise to 23.6 million per year in the U.S. alone. Along with increased deaths, spending on drugs to treat CVD as well as related hospital stays, home health care and lost productivity will also…
Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH and a developer of pioneering solutions for the detection of genetic resistances in pathogens, announced that the project "GEAR - Predicting Antibiotic Resistances with Genetic Data" has been awarded in the competition "Landmarks in the Land of Ideas".
Visiopharm A/S announces the first result of their multifaceted strategy to apply Deep Learning technologies to its leading image analysis solution for cancer research and diagnostics. Visiopharm considers Deep Learning an important technological breakthrough for tissue pathology that offers the potential to make a real difference in the assessment of tissue structures, which is probably one of…
As the South Korean epidemic of Middle East Respiratory Syndrome (MERS) continues unabated, researchers have raced to find treatments for the deadly virus, which has killed more than 400 people since it was first discovered three years ago in Saudi Arabia.
GE and Thermo Fisher Scientific announced yesterday that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion.
Samsung BioLogics today announced that Samsung BioLogics and F. Hoffmann-La Roche have entered into a long term strategic manufacturing agreement under which Samsung will manufacture Roche's proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, of which one is currently under construction.
The international research project ‘The Definition of new types of tumours containing potential mutations sensitivity to drugs’ has begun in Petrov Research Institute of Oncology in St Petersburg, the oldest Russian oncology institute.
GE Healthcare announced today its plans to dedicate $1 billion of its total R&D budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities, as well as its world-class technologies for the manufacture of biopharmaceuticals and for cancer research.
The IMS Institute for Healthcare Informatics today reported that global spending for medicines will reach nearly $1.1 trillion by 2015, reflecting a slowing compound annual growth rate of 3-6 percent over the next five years. This compares with 6.2 percent annual growth over the past five years.
GE announced today the formation of the GE Healthymagination Fund, a new equity fund that will make investments in highly promising healthcare technology companies. The fund will invest in companies globally that have innovative diagnostic, IT, and life sciences technologies aligned with the strategic objectives of GE´s Healthymagination initiative. The fund will also support healthcare…
Positive CB7630 (Abiraterone Acetate) Phase II Data was presented at the ASCO Annual Meeting in Chicago this May/June, Cougar Biotechnology Inc, a development stage biopharmaceutical firm with a specific focus on oncology. In mid-July, Johnson & Johnson announced its acquisition of Cougar, which is now working with Ortho Biotech Oncology Research & Development, a division of the J&J firm Centocor…
London and Cambridge-based biopharmaceutical research firm Domainex Ltd has received a European patent for its Combinatorial Domain Hunting (CDH) Technology, which enables the cloning and expression of recombinant proteins, or parts of proteins (domains), from challenging molecular targets.
Transition Therapeutics Inc. announced that the first patient has been dosed in a Phase 2 clinical study of gastrin analogue, TT-223, in patients with type 2 diabetes. Gastrin based therapies are an emerging class of potential disease-modifying treatments for patients with diabetes.
Arlington Medical Resources (AMR), a pharmaceutical market research firm, found that the number of patients treated with an antibiotic associated with MRSA-infections within U.S. acute care hospitals has increased 8 percent by the last year. But the average time MRSA-patients had to stay in hospital decreased by 10 percent.
Bayer and its affiliated firm Icon Genetics developed an own production process which provides the opportunity to make therapeutic proteins from tobacco plants. The pilot plant for biotech drugs opened on June 16 in Halle, Saxony-Anhalt.
A new research collaboration to study the potential of microbubbles and ultrasound to treat ischemic strokes has been established between ImaRx Therapeutics, a biopharmaceutal company in Tucson, Arizona, and the Philips' Medical Systems division in Andover, Massachusetts.
The European Parliament voted for an EU Regulation on advanced therapies like gene therapy, cell therapy and tissue engineering. The decision, if adopted by the council, could open the door for innovative therapies which have a huge potential for curing diseases such as Parkionson´s, Alzheimer or cancer.
Innovative materials and technologies for medical devices are on show by GE Plastics.
AIDS, SARS and now H5NI; just a brief beginning or the end? As the virus moves towards Europe, and millions of birds are slaughtered, interest has risen in a Chinese herb, a patent-sharing controversy and drug stockpiling